Cosmos Health CEO Greg Siokas acquired a total of 647,809 shares worth $425,000 in the last 32 days By Investing.com

Spread the love

Chicago, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. (“Cosmos Health” or the “Company”). (NASDAQ:Greg Tsiokas, CEO of the diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceuticals and nutritional products, manufacturer and distributor of healthcare products and operator of telehealth platforms, has announced that he has raised his stake in the company. The company acquired a total of 647,809 shares of common stock valued at $425,000 in six transactions between December 20, 2024 and January 17, 2025.

As a result of these transactions, Mr. Siokas now owns 4,164,789 common shares in Cosmos Health.

According to Greg Siokas, CEO of Cosmos Health: “I am incredibly excited about the prospects for our future, having invested more than $17 million to support Cosmos since its inception. We are in a time of transformation, and I will continue to support our efforts as we advance our strategy and vision, moving our exciting projects forward and expanding our brands globally.”

Information on Mr. Siokas’s recent transactions:

Please refer to the SEC filing on Form 4 and the SEC website for more information about the nature of the transactions, such as “Ownership Form.” Marketing (JO:) Date, “Amount”, “Price” and other important information about the shares acquired by Mr. Siokas.

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in Nevada in 2009, is a diversified, vertically integrated global healthcare group. The company owns a portfolio of proprietary pharmaceutical and nutritional products including Sky Premium Life ® , Mediterranation ® , bio-bebe ® , C-Sept ® and C-Scrub ® . It manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices in the European Union under a subsidiary of Cana Laboratory SA, licensed by European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA). Cosmos Health also distributes a wide line of pharmaceuticals and pharmaceuticals, including branded generics and OTC medicines, to retail pharmacies and wholesalers through subsidiaries in Greece and the UK. In addition, the company has established R&D partnerships that target major health conditions such as obesity, diabetes and cancer enhanced by artificial intelligence drug recycling technologies and focuses on new patented ingredients, unique root extracts, proprietary complex genetics and innovative OTC. Products. Cosmos Health has entered the telehealth space by acquiring ZipDoctor Inc. based in Texas, USA. With a global distribution platform, the company is currently expanding throughout Europe, Asia and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece and Hallow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.

Forward-looking statements

Except for the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. , as amended. includes the preceding, following, or otherwise, “believes,” “expects,” “anticipates,” “expects,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs. Words such as “will”, “should”, “will”, “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially affect the matters discussed, including but not limited to factors beyond the Company’s control, including, but not limited to, the Company’s ability to raise sufficient financing to carry out its operations. business plan, the impact of the COVID-19 pandemic and the war in Ukraine on the Company’s business, operations and the general economy, and the ability to successfully develop and commercialize the Company’s proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed in the forward-looking statements contained herein. Readers are urged to read the risk factors listed in the company’s filings with the SEC, which are available on the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise, any forward-looking statements as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG connections
cosm@bdgcommunications.com
+44 207 0971 653

Source: Cosmos Health Inc.

See the original press release on ACCESS Newswire

Similar Posts